Who is sponsoring NCT01113268?

NCT01113268 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT01113268?

Interventions in NCT01113268: Cohort.

What condition does NCT01113268 study?

NCT01113268 studies ST Elevation (STEMI) Myocardial Infarction of Other Sites.

Is NCT01113268 still recruiting?

NCT01113268 is currently terminated. Last updated 25 August 2023.

Last reviewed 2023-08-25 · How we verify

NCT01113268: PREGICA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PREdisposition Genetical in Cardiac Insufficiency = Genetic Predisposition to Heart Failure

Terminated NA Last updated 25 August 2023

What this trial tests

NA trial testing Cohort in ST Elevation (STEMI) Myocardial Infarction of Other Sites in 658 participants. Terminated before completion.

Timeline

30 September 2010

Primary endpoint
30 September 2017

23 August 2023

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	658
Start date	30 September 2010
Primary completion	30 September 2017
Estimated completion	23 August 2023
Sites	1 location across France

Drugs / interventions tested

Cohort

Conditions studied

ST Elevation (STEMI) Myocardial Infarction of Other Sites — all drugs for ST Elevation (STEMI) Myocardial Infarction of Other Sites →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 18 to 80, any sex, with ST Elevation (STEMI) Myocardial Infarction of Other Sites. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach. Our main hypothesis is that there is, for a given initial biomechanical stress (duration of the ischemic episode, size of the infarcted area, etc.), a variation in the individual susceptibility to develop left ventricular remodelling and to progress towards heart failure, and that this variation is linked to genetic variants between individuals.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Novel Cardiokine GDF3 Predicts Adverse Fibrotic Remodeling After Myocardial Infarction.
Masurkar N, Bouvet M, Logeart D, Jouve C, et al · · 2023 · cited 21× · PMID 36484260 · DOI 10.1161/circulationaha.121.056272
Circular RNA-mediated regulation of key signaling pathways in cardiovascular diseases: a review.
You Q, Zhang W, Koo C, Jia C, et al · · 2026 · cited 4× · PMID 41015177 · DOI 10.1016/j.jare.2025.09.048
Predicted Value of MicroRNAs, Vascular Endothelial Growth Factor, and Intermediate Monocytes in the Left Adverse Ventricular Remodeling in Revascularized ST-Segment Elevation Myocardial Infarction Patients.
Del Toro R, Galeano-Otero I, Bevilacqua E, Guerrero-Márquez F, et al · · 2022 · cited 1× · PMID 35402537 · DOI 10.3389/fcvm.2022.777717
Crosstalk between circulating DPP3 and immune cells in the context of cardio-systemic stress.
Assad N, Nordin H, Nguyen A, Oddos C, et al · · 2026 · PMID 41847607 · DOI 10.1016/j.isci.2026.115114

Verify or expand the search:

Other trials of Cohort

Trials testing the same drug.

NCT07028112 — Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematop · not yet recruiting
NCT05440656 — A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated W · completed
NCT04386759 — COVID-19 Infection in Healthcare Workers · completed
NCT03607344 — Day Case Laparoscopic Sacrocolpopexy, a New Management · completed
NCT05029648 — Evaluation of Predictive Factors for Psoas Tendinitis After First-line Total Hip Arthroplasty · completed

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01113268 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 25 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01113268.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing